Therapeutic targets in dry eye syndrome
Therapeutic targets in dry eye syndrome
复制标题
DOI：
10.1358/dnp.2008.21.3.1203413
复制
发表时间：
2008-04-01
影响因子：
--
通讯作者：
Pintor, Jesus
中科院分区：
文献类型：
--
作者：
Peral, Assumpta;Dominguez-Godinez, Carmen O.;Pintor, Jesus
干眼是一种泪液和眼表的多因素疾病，表现为各种体征和症状。它在全球约33%的人口中流行。由于病理学的重要性，已经开发了新的测试、药物和技术来辅助疾病的诊断、管理和随访。目前可用的治疗方法试图缓解症状和减少体征，以恢复眼表。根据病理的病因，可以单独或联合使用润滑剂、促分泌剂、生物泪液替代品或抗炎药。目前，临床试验中的治疗方法主要用于刺激泪液成分(如P2Y受体激动剂地夸福索)或粘蛋白分泌(如雷帕米特，一种喹诺酮的氨基酸类似物)。其他包括吉法酯，一种水不溶的萜类脂肪酸，有助于恢复眼睛表面的粘蛋白，或西维米林，一种口服胆碱能激动剂，可以减少与干眼相关的症状。专利中描述的其他潜在化合物处于药物开发的较低阶段。这些化合物来自不同的疗法家族，其中包括类固醇和非类固醇抗炎药、维生素A和D、神经递质和神经肽。(C)2008年光辉科学协会或其许可人。版权所有。
Dry eye is a multifactorial disease of the tears and the ocular surface that manifests with a wide variety of signs and symptoms. It is prevalent in about 33% of the population worldwide. Due to the importance of the pathology, new tests, drugs and technologies have been developed to assist the diagnosis, management and follow-up of the disease. Current available therapies try to alleviate symptoms and to reduce signs in order to restore the ocular surface. Depending on the etiology of the pathology it is possible to use lubricants, secretagogues, biological tear substitutes or antiinflammatory drugs, either independently or combined. Nowadays, the therapies under clinical trial are devoted to stimulating tear components (e.g., diquafosol, a P2Y receptor agonist), or mucin secretion (e.g., rebamipide, an amino acid analogue of quinolinone). Others include gefarnate, a water-insoluble terpene fatty acid that contributes to restoring mucins on the ocular surface, or cevimeline, an oral cholinergic agonist that reduces the symptoms associated with dry eye. Other potential compounds described in patents are in a lower phase of drug development. These compounds come from different families of therapies, and among others, can be found in the form of steroidal and nonsteroidal antiinflammatory agents, vitamins A and D, neurotransmitters and neuropeptides. (C) 2008 Prous Science, S.A.U. or its licensors. All rights reserved.